HER2-expressing
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma (NCT05302284) | RemeGen Co., Ltd. | 2022-06-14 |
Track HER2-expressing automatically
Every clearance here is in the API, with alerts when new ones post.